Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study

Table 1 Patient backgrounds treated with CHOP or R-CHOP regimen in malignant lymphoma with or without aprepitant

	Total	Aprepitant regimen group	Control regimen group	p value
No. of patients	39	15	24
Age
Median (range)		60 (37–75)	67 (27–76)	0.71
< 50 years	6	2	4	0.063
> 50 years	33	13	20	0.063
Sex
Male	19	6	13	0.042
Female	20	9	11	0.042
R-CHOP	25	8	17	0.029
CHOP	14	7	7	0.029
Type of histology
FL	6	3	3	0.049
DLBCL	22	7	15	0.036
Other^a	11	5	6	0.053
RDI of CHOP (%)		94	91	0.33

Statistical analyses were performed with the Chi-squared test
(%) Relative dose intensity (RDI) = dose intensity (mg/m²/week)/planned dose intensity (mg/m²/week) × 100
Abbreviations: R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, CHOP Cyclophosphamide, doxorubicin, vincristine, predonisolone, FL Follicular lymphoma, DLBCL Diffuse large B-cell lymphoma
^aPTCL, peripheral T cell lymphoma; ALCL, anaplastic large cell lymphoma, AITL, angioimmunoblastic T cell lymphoma; IVL, intravascular lymphoma

ISSN: 2055-0294